GNTA - היקף יתרות המזומנים של החברה genenta.com

Genenta Science S.p.A. (GNTA) is developing a unique genetic brain defense using stem cells and patented tumor-fighting methods. The organization's cash balances clearly illustrate the financial dynamics, where 0.02 records the value of this parameter. Meanwhile, production and testing have been outsourced to external contractors, and the R&D stage for solid tumors is temporarily increasing unit costs during the scaling of research.
פילוחי מדדים פיננסיים ומדדי שוק עבור Genenta Science S.p.A. (GNTA)

As an innovative leader in gene therapy for solid tumors, Genenta Science S.p.A. (GNTA) requires significant R&D capital expenditures, making the volume of liquid assets a critical factor for survival. This metric measures the total balance of cash and cash equivalents, allowing for an assessment of the company's ability to cover operating expenses without incurring external debt. By analyzing changes in cash reserves, an investor can timely identify the risk of a liquidity gap or an inefficient capital surplus.